BioCentury
VerifiedOnline/Digital
Since 1993, BioCentury, Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.
BioCentury's Editorial and Research staff comprise industry-recognized business and science editors and writers. The Company's management team includes executives with backgrounds in international business, publishing, finance, and the biotech and pharmaceutical industries.
BioCentury is headquartered in Redwood City, Calif., with offices in Washington, D.C.; Chicago; and London. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesMaking center directors permanent latest signal of stability for FDA
ARTICLE | Politics, Policy & Law ‘Acting’ no more: HHS signals intent to maintain current direction with appointments of Davis, Mikhail By Steve Usdin, Washington Editor In a move that solidifies FDA’s operational leadership, the Trump administration has made Michael Davis CDER Director and Karim Mikhail CBER Director. They had been serving as acting center directors since May. Jared Seehafer has been named to a new position, Deputy Commissioner for Technology and Artificial Intelligence.
The factors that could have contributed to Novartis’ Lp(a) miss
ARTICLE | Product Development Antisense therapy pelacarsen from Novartis failed to improve cardiovascular outcomes in Phase III By Lauren Martz, Executive Director, Biopharma Intelligence The Phase III miss by Novartis’ pelacarsen is a blow to the pharma’s first-in-class Lp(a) aspirations. Depending on what the full data show — and whether subsequent programs succeed — it could also have implications for antisense oligos, other RNA modalities, and cardiovascular R&D more broadly.
Novartis’ Phase III misses, pharma deals analysis, MFN carve-outs — a BioCentury podcast
PODCAST | Product Development Plus: A tribute to Peter Barton Hutt, who helped shape drug law for decades By BioCentury Staff • Novartis and Lp(a) fallout — Pelacarsen's Phase III failure has shaken confidence in a genetically supported cardiovascular target and ignited a debate over whether issues with the target, modality or treatment setting contributed to the lack of efficacy.
Novartis’ Phase III misses compound Novo’s cardiovascular setback
ARTICLE | Product Development BioCentury’s Clinical Report, Sept. 4-8 By Tierney Baum, Biopharma Analyst Novartis reported two Phase III misses over the past five days, while Novo halted two late-stage heart failure trials following the failure of an earlier cardiovascular outcomes study. In both companies’ cardiovascular programs, successful target engagement failed to translate into clinical benefit.
FDA solidifies CDER, CBER leadership
ARTICLE | Politics, Policy & Law By making acting directors Davis, Mikhail permanent, HHS signals intent to maintain current direction, stabilize FDA By Steve Usdin, Washington Editor In a move that solidifies FDA’s operational leadership, the Trump administration has made Michael Davis CDER Director and Karim Mikhail CBER Director. They had been serving as acting center directors since May.
GSK takes rights to Hutchmed’s KRAS-antibody conjugate: Deals Report
ARTICLE | Deals Plus: Alteogen’s latest deal for delivery tech is with Novartis; Menarini in-licenses local rights to Gan & Lee obesity program; and more By Paul Bonanos, Director of Biopharma Intelligence, and TK An agreement giving GSK shared rights to a dual-targeted oncology therapy is the first deal from Hutchmed’s innovative platform, following the start of clinical trials of two other programs designed using the same technology.
Cloverleaf: Turning 5-FU’s overlooked RNA mechanism into a new payload
ARTICLE | Emerging Company Profile Yale spinout lands a $33M pharma-backed seed round to develop antibody conjugates carrying engineered tRNA payloads By Danielle Golovin, Senior Biopharma Analyst Cloverleaf is turning the RNA-disrupting mechanism of one of the oldest chemotherapies into a new class of targeted cancer payloads.
Gan & Lee’s first big cross-border deal aids Menarini push into obesity
ARTICLE | Deals Data for twice-monthly GLP-1R agonist were competitive vs. market leaders Zepbound and Wegovy By Stephen Hansen, Director of Biopharma Intelligence Italian pharma Menarini is making its first push into obesity via a licensing deal with Beijing-based Gan & Lee for twice-monthly GLP-1R agonist bofanglutide, which has showed strong efficacy data compared with market leader Zepbound tirzepatide.
Six first-in-class approvals in August
DATA GRAPHICS | Data Byte Banner month at CBER, with 3 new BLAs approved By Meredith Durkin Wolfe, Director of Research August was a banner month for first-in-class drug approvals, with six of the seven NMEs FDA approved representing new targets or combination of products. These most fanfare among these first-in-class drugs went to RAS(ON) inhibitor Rasonque daraxonrasib from Revolution Medicines Inc.
Pharma deals: Embracing disruptive technologies
ARTICLE | Deals Deals by 21 top pharmas in 2H25-1H26 cluster in breakthrough new technologies By Lauren Martz, Executive Director, Biopharma Intelligence The past 12 months of pharma dealmaking reflect a collective push into disruptive technologies with the power to create new drug markets and overhaul the way diseases are treated.